Navigation Links
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
Date:11/3/2008

nically meaningful and important regulatory endpoint. The apparent prolongation in PFS of 4.5 months, compared to a historical expectation of 1.7 months, combined with clear objective responses and tumor reduction in the majority of patients, suggests that CR011-vcMMAE has the potential to become an important novel therapy in this patient population," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen.

As expected based upon the expression of GPNMB and as observed in Phase I, dermatologic adverse events consisting of rash, alopecia, and pruritus were the most common toxicities in this study. A preliminary exploratory analysis assessing the relationship of rash and PFS was performed and showed a trend toward longer PFS in patients that developed Grade 2 or higher rash (n=13). Other adverse events included fatigue, diarrhea, anorexia and nausea. Grade 3 or 4 neutropenia was observed in 7 patients (22%).

"The target of CR011-vcMMAE, GPNMB, is a protein that is believed to be over expressed in a variety of tumors and also present in some normal tissue including the skin. The preliminary data which may suggest a correlation between the development of rash and clinical efficacy is very intriguing and we will continue to assess its potential role in helping to identify those patients who may best respond to treatment with CR011-vcMMAE," commented Dr. Ronit Simantov, Chief Medical Officer at CuraGen. "We would like to thank our investigators for their enthusiasm, which we believe is highlighted by their ability to fully enroll this Phase II trial in just 6 months, and we look forward to reporting the final data from this Phase II trial during the first half of 2009."

"Targeting GPNMB with this antibody-drug conjugate represents a potentially novel way to treat this disease, and based on these preliminary Phase II results, CR011-vcMMAE appears to be clinically active against unresectable melanoma in some patients. We look for
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
(Date:8/21/2014)... August 21, 2014 BreedIT ... Ltd., the exclusive worldwide license holder and distributor ... breeders and researchers, today is pleased to announce ... with Seach Ltd, a leading Israeli medical Cannabis ... and develop new breeds of medical Cannabis to ...
(Date:8/21/2014)... 2014  AliveCor, Inc. announced today that ... has granted the company clearance for its ... most common form of cardiac arrhythmia. AliveCor,s ... patients are experiencing AFib through real-time electrocardiogram ... based AliveCor® Heart Monitor, so physicians can ...
Breaking Medicine Technology:Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2
(Date:8/21/2014)... a challenge. Thankfully, there are Zombies chasing you. , At ... 31,000 health and fitness apps on the market today, and ... to increase physical activity. , Gamification is currently the popular ... to help people get fit. Whether or not it,s the ... just been assumed that gamified apps will work, but there ...
(Date:8/21/2014)... Dallas, TX (PRWEB) August 21, 2014 ... August 20 entertained residents with dementia at Silverado Turtle ... Improv Troupe, which consists of entertainers ranging from ages ... each time they perform their 40-minute set. The troupe's ... makes it universal and allows them to touch audiences ...
(Date:8/21/2014)... (Boston) African American women born at a low ... higher risk for developing type 2 diabetes. The findings, ... in part the higher occurrence of type 2 diabetes ... of low birth weight. , Researchers from Boston University,s ... in the Black Women,s Health Study over the course ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Not only is eating ... save them hundreds of health-care dollars a year, a new ... professor of public health sciences at Wake Forest Baptist Medical ... and obese type 2 diabetes patients. Participants ... assigned to either an intensive "lifestyle change program" focused on ...
(Date:8/21/2014)... Thompson HealthDay Reporter ... of therapy and antidepressants appears to best help people ... Four out of five people suffering from severe ... when treated with cognitive therapy plus antidepressant medication, researchers ... work much better than drugs alone in helping people ...
Breaking Medicine News(10 mins):Health News:Playing hunger games: Are gamified health apps putting odds in your favor? 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Low birth weight linked to higher incidence of type 2 diabetes in African American women 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3
... Funding Cuts in 2009 Will Reduce Payments for Home Oxygen ... WASHINGTON, Dec. 31 As Americans nationwide prepare to celebrate ... 2009 with great unease due to significant Medicare policy changes ... On January 1, two new policies in the form ...
... WEDNESDAY, Dec. 31 (HealthDay News) -- Be careful with the ... in the ER this holiday season with an eye injury ... is opened improperly, the cork can travel up to 50 ... an eye, according to the American Academy of Ophthalmology. , ...
... to help dieters,stick to their New Year,s resolution ... of Plan-a-Meal software that is iPhone and BlackBerry,friendly. ... easily customize their meal plans throughout the day ... keystrokes, dieters can quickly,include restaurant and take-out meals, ...
... The HealthCare Solution, today announced the company is radically changing the ... approach, the California health insurance provider has partnered with top UK ... reduce their risk of memory loss that often times affects health ... ...
... the gold standard for grading, staging and "stad-ging" the ... source for acquiring new knowledge on the liver pathology. ... tissue detectable in liver biopsy samples has been fuelled ... new antiviral molecules on the lesions characterising the histological ...
... Alternext US: CXM) reported notification from the staff ... is currently considered to be,noncompliant with certain listing ... American Stock Exchange). Based on the company,s ... November 10, 2008, noncompliance was,noted with respect to ...
Cached Medicine News:Health News:Massive Cuts to Medicare Home Oxygen Therapy Benefit Taking Effect January 1 Creating Acute Anxiety Among Beneficiary and Provider Communities 2Health News:Massive Cuts to Medicare Home Oxygen Therapy Benefit Taking Effect January 1 Creating Acute Anxiety Among Beneficiary and Provider Communities 3Health News:PersonalDiets Announces New Plan-A-Meal Tools to Help With New Year's Weight Loss Resolutions! 2Health News: Baby-Boomers Find Help Qualifying for California Health Insurance with UK Neurosurgeon, Sim Farar 2Health News:A rigorous method for liver biopsy 2Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 2Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 3Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 4Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 5
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: